BRBrinda K. Rana

Brinda K. Rana

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Brinda K. Rana has a total of 146 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Metabolome Alterations Associated with Three-Month Sitting-Time Reduction Among Sedentary Postmenopausal Latinas with Cardiometabolic Disease Risk

    by Jeffrey S. Patterson, Paniz Jasbi, Yan Jin, Haiwei Gu, Matthew A. Allison, Chase Reuter, Brinda K. Rana, Loki Natarajan, Dorothy D. Sears

    Background: Incidence of cardiometabolic disease among U.S. Hispanics/Latinos is higher than in non-Hispanic Whites. Prolonged sitting duration is prevalent in older adults, and compounded with menopause, greatly increases cardiometabolic risk in postmenopausal women. Metabolomic analyses of interventions to reduce sitting are lacking and mechanistic understanding of health-promoting behavior change in postmenopausal Latinas is needed. Methods: To address this knowledge gap, an exploratory analysis investigated the plasma metabolome impact of a 12-week increased standing intervention among sedentary postmenopausal Latinas with overweight or obesity. From a parent-randomized controlled trial, a subset of Best Responders (n = 43) was selected using parameters of highest mean change in sitting bout duration and total sitting time; baseline variable-Matched Controls (n = 43) were selected using random forest modeling. Targeted LC-MS/MS analysis of archived baseline and 12-week plasma samples was conducted. Metabolite change was determined using a covariate-controlled general linear model and multivariate testing was performed. A false discovery rate correction was applied to all analyses. Results: Best Responders significantly changed time sitting (−110.0 ± 11.0 min; −21%), standing (104.6 ± 10.1 min; 40%), and sitting in bouts >30 min (−102.3 ± 13.9 min; −35%) compared to Matched Controls (7.1 ± 9.8 min, −7.8 ± 9.0 min, and −4.6 ± 12.7 min, respectively; all p < 0.001). Twelve-week metabolite change was significantly different between the two groups for 24 metabolites (FDR < 0.05). These were primarily related to amino acid metabolism, improved blood flow, and ATP production. Enzyme enrichment analysis predicted significant changes regulating glutamate, histidine, phenylalanine, and mitochondrial short-chain fatty acid catabolism. Pathway analysis showed significant intervention effects on glutamate metabolism and phenylalanine, tyrosine, and tryptophan biosynthesis, potentially indicating reduced cardiometabolic disease risk. Conclusions: Replacing nearly two hours of daily sitting time with standing and reduced prolonged sitting bouts significantly improved metabolomic profiles associated with cardiometabolic risk among postmenopausal Latinas.


  • Open Access

    Sitting Interruption Modalities during Prolonged Sitting Acutely Improve Postprandial Metabolome in a Crossover Pilot Trial among Postmenopausal Women

    by Jeffrey S. Patterson, Brinda K. Rana, Haiwei Gu, Dorothy D. Sears

    Older adults sit during most hours of the day; more than 30% are considered physically inactive. The accumulation of prolonged sitting time is an exercise-independent risk factor for aging-related conditions such as cardiometabolic disease and cancer. Archival plasma samples from a randomized controlled, four-condition crossover study conducted in 10 postmenopausal women with overweight or obesity were analyzed. During 5-hour conditions completed on separate days, the trial tested three interruption modalities: two-minute stands each 20 min (STS), hourly ten-minute standing breaks (Stand), hourly two-minute walks (Walk), and a controlled sit. Fasting baseline and 5-hour end point (2 h postprandial) samples were used for targeted metabolomic profiling. Condition-associated metabolome changes were compared using paired t-tests. STS eliminated the postprandial elevation of amino acid metabolites that was observed in the control. A norvaline derivative shown to have anti-hypertensive and -hyperglycemic effects was significantly increased during Stand and STS. Post-hoc testing identified 19 significantly different metabolites across the interventions. Tight metabolite clustering by condition was driven by amino acid, vasoactive, and sugar metabolites, as demonstrated by partial least squares-discriminant analyses. This exploratory study suggests that brief, low-intensity modalities of interrupting prolonged sitting can acutely elucidate beneficial cardiometabolic changes in postmenopausal women with cardiometabolic risk.


  • Top Cited Papers

    The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight

    by Francine E. Garrett-Bakelman, Manjula Darshi, Stefan J. Green, Ruben C. Gur, Ling Lin, Brandon R. Macias, Miles J. McKenna, Cem Meydan, Tejaswini Mishra, Jad Nasrini, et al.

    What to expect after a year in space: Space is the final frontier for understanding how extreme environments affect human physiology. Following twin astronauts, one of which spent a year-long mission on the International Space Station, Garrett-Bakelman et al. examined molecular and physiological traits that may be affected by time in space (see the Perspective by Löbrich and Jeggo). Sequencing the components of whole blood revealed that the length of telomeres, which is important to maintain in dividing cells and may be related to human aging, changed substantially during space flight and again upon return to Earth. Coupled with changes in DNA methylation in immune cells and cardiovascular and cognitive effects, this study provides a basis to assess the hazards of long-term space habitation. Science , this issue p. eaau8650 ; see also p. 127


  • Association of Sleep Quality on Memory-Related Executive Functions in Middle Age

    by Brinda K. Rana, Matthew S. Panizzon, Carol E. Franz, Kelly M. Spoon, Kristen C. Jacobson, Hong Xian, Sonia Ancoli-Israel, Michael Lyons, William S. Kremen

    Objectives:Sleep quality affects memory and executive function in older adults, but little is known about its effects in midlife. If it affects cognition in midlife, it may be a modifiable factor for later-life functioning.Methods:We examined the association between sleep quality and cognition in 1220 middle-aged male twins (age 51–60 years) from the Vietnam Era Twin Study of Aging. We interviewed participants with the Pittsburgh Sleep Quality Index and tested them for episodic memory as well as executive functions of inhibitory and interference control, updating in working memory, and set shifting. Interference control was assessed during episodic memory, inhibitory control during working memory, and non-memory conditions and set shifting during working memory and non-memory conditions.Results:After adjusting for covariates and correcting for multiple comparisons, sleep quality was positively associated with updating in working memory, set shifting in the context of working memory, and better visual-spatial (but not verbal) episodic memory, and at trend level, with interference control in the context of episodic memory.Conclusions:Sleep quality was associated with visual-spatial recall and possible resistance to proactive/retroactive interference. It was also associated with updating in working memory and with set shifting, but only when working memory demands were relatively high. Thus, effects of sleep quality on midlife cognition appear to be at the intersection of executive function and memory processes. Subtle deficits in these age-susceptible cognitive functions may indicate increased risk for decline in cognitive abilities later in life that might be reduced by improved midlife sleep quality. (JINS, 2018,24, 67–76)


  • Open Access

    The IL6 Gene Promoter SNP and Plasma IL-6 in Response to Diet Intervention

    by Brinda K. Rana, Shirley W. Flatt, Dennis D. Health, Bilge Pakiz, Elizabeth L. Quintana, Loki Natarajan, Cheryl L. Rock

    We recently reported that interleukin-6 (IL-6), an inflammatory marker associated with breast pathology and the development of breast cancer, decreases with diet intervention and weight loss in both insulin-sensitive and insulin-resistant obese women. Here, we tested whether an individual’s genotype at an IL6 SNP, rs1800795, which has previously been associated with circulating IL-6 levels, contributes to changes in IL-6 levels or modifies the effect of diet composition on IL-6 in these women. We genotyped rs1800795 in overweight/obese women (N = 242) who were randomly assigned to a lower fat (20% energy), higher carbohydrate (65% energy) diet; a lower carbohydrate (45% energy), higher fat (35% energy) diet; or a walnut-rich (18% energy), higher fat (35% energy), lower carbohydrate (45% energy) diet in a 1-year weight loss intervention study of obesity-related biomarkers for breast cancer incidence and mortality. Plasma IL-6 levels were measured at baseline, 6 and 12 months. At baseline, individuals with a CC genotype had significantly lower IL-6 levels than individuals with either a GC or GG genotype (p < 0.03; 2.72 pg/mL vs. 2.04 pg/mL), but this result was not significant when body mass index (BMI) was accounted for; the CC genotype group had lower BMI (p = 0.03; 32.5 kg/m2 vs. 33.6 kg/m2). We did not observe a 2-way interaction of time*rs1800795 genotype or diet*rs1800795 genotype. Our findings provide evidence that rs1800795 is associated with IL-6 levels, but do not support a differential interaction effect of rs1800795 and diet composition or time on changes in circulating IL-6 levels. Diet intervention and weight loss are an important strategy for reducing plasma IL-6, a risk factor of breast cancer in women, regardless of their rs1800795 genotype.


  • Acute psychological stress induces short-term variable immune response

    by Michael S. Breen, Nadejda Beliakova-Bethell, Lilianne R. Mujica-Parodi, Joshua M. Carlson, Wayne Y. Ensign, Christopher H. Woelk, Brinda K. Rana


  • Imputing Observed Blood Pressure for Antihypertensive Treatment: Impact on Population and Genetic Analyses

    by Brinda K. Rana, Anish Dhamija, Matthew S. Panizzon, Kelly M. Spoon, Terrie Vasilopoulos, Carol E. Franz, Michael D. Grant, Kristen C. Jacobson, Kathleen Kim, Michael J. Lyons, et al.

    Elevated blood pressure (BP), a heritable risk factor for many age-related disorders, is commonly investigated in population and genetic studies, but antihypertensive use can confound study results. Routine methods to adjust for antihypertensives may not sufficiently account for newer treatment protocols (i.e., combination or multiple drug therapy) found in contemporary cohorts. We refined an existing method to impute unmedicated BP in individuals on antihypertensives by incorporating new treatment trends. We assessed BP and antihypertensive use in male twins (n = 1,237) from the Vietnam Era Twin Study of Aging: 36% reported antihypertensive use; 52% of those treated were on multiple drugs. Estimated heritability was 0.43 (95% confidence interval (CI) = 0.20-0.50) and 0.44 (95% CI = 0.22-0.61) for measured systolic BP (SBP) and diastolic BP (DBP), respectively. We imputed BP for antihypertensives by 3 approaches: (i) addition of a fixed value of 10/5mm Hg to measured SBP/DBP; (ii) incremented addition of mm Hg to BP based on number of medications; and (iii) a refined approach adding mm Hg based on antihypertensive drug class and ethnicity. The imputations did not significantly affect estimated heritability of BP. However, use of our most refined imputation method and other methods resulted in significantly increased phenotypic correlations between BP and body mass index, a trait known to be correlated with BP. This study highlights the potential usefulness of applying a representative adjustment for medication use, such as by considering drug class, ethnicity, and the combination of drugs when assessing the relationship between BP and risk factors.


  • Open Access

    Genetic and environmental influences on sleep quality in middle‐aged men: a twin study

    by Margo R. Genderson, Brinda K. Rana, Matthew S. Panizzon, Michael D. Grant, Rosemary Toomey, Kristen C. Jacobson, Hong Xian, Alice Cronin‐Golomb, Carol E. Franz, William S. Kremen, et al.

    Summary: Poor sleep quality is a risk factor for a number of cognitive and physiological age‐related disorders. Identifying factors underlying sleep quality are important in understanding the etiology of these age‐related health disorders. We investigated the extent to which genes and the environment contribute to subjective sleep quality in middle‐aged male twins using the classical twin design. We used the Pittsburgh Sleep Quality Index to measure sleep quality in 1218 middle‐aged twin men from the Vietnam Era Twin Study of Aging (mean age = 55.4 years; range 51–60; 339 monozygotic twin pairs, 257 dizygotic twin pairs, 26 unpaired twins). The mean PSQI global score was 5.6 [SD = 3.6; range 0–20]. Based on univariate twin models, 34% of variability in the global PSQI score was due to additive genetic effects (heritability) and 66% was attributed to individual‐specific environmental factors. Common environment did not contribute to the variability. Similarly, the heritability of poor sleep—a dichotomous measure based on the cut‐off of global PSQI>5—was 31%, with no contribution of the common environment. Heritability of six of the seven PSQI component scores (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, and daytime dysfunction) ranged from 0.15 to 0.31, whereas no genetic influences contributed to the use of sleeping medication. Additive genetic influences contribute to approximately one‐third of the variability of global subjective sleep quality. Our results in middle‐aged men constitute a first step towards examination of the genetic relationship between sleep and other facets of aging.


  • Receptor Databases and Computational Websites for Ligand Binding

    by Brinda K. Rana, Philip E. Bourne, Paul A. Insel

    Ligand binding to receptors is a key step in the regulation of cellular function by neurotransmitters, hormones, and many drugs. Not surprisingly then, genome projects have found that families of receptor genes form the largest groups of functional genes in mammalian genomes. A large body of experimental data have thus been generated on receptor–ligand interactions, and in turn, numerous computational tools for the in silico prediction of receptor–ligand interactions have been developed. Websites containing ligand binding data and tools to assess and manipulate such data are available in the public domain. Such Websites provide a resource for experimentalists studying receptor binding and for scientists interested in utilizing large data sets for other purposes, which include modeling structure–function relationships, defining patterns of interactions of drugs with different receptors, and computational comparisons among receptors. The Websites include databases of receptor protein and nucleotide sequences for particular classes of receptors (such as G-protein-coupled receptors and nuclear receptors) and of experimental results from receptor–ligand binding assays, as well as computational tools for modeling the interactions between ligands and receptors and predicting the function of orphan receptors. In this chapter, we provide information and Uniform Resource Locators (URLs) for Websites that facilitate computational and experimental studies of receptor–ligand interactions. This list will be periodically updated at https://sites.google.com/site/receptorligandbinding/.


  • Isoprostane, an “Intermediate Phenotype” for Oxidative Stress

    by Fangwen Rao, Kuixing Zhang, Srikrishna Khandrika, Manjula Mahata, Maple M. Fung, Michael G. Ziegler, Brinda K. Rana, Daniel T. O'COnnor